Inside Lonza Group: Revenue Trends, Strategic Moves, and Competitive Outlook

Lonza Group, a Swiss multinational manufacturing company, holds a largely understated yet foundational position within the global nutraceutical and pharmaceutical sectors. While not a household name, its ubiquitous Capsugel and DRcaps technologies mean that a significant proportion of the world's encapsulated supplements and medications are housed in its products. For B2B players in the supplement industry, Lonza represents both a critical supplier and a barometer for market trends, particularly in advanced delivery systems and contract manufacturing.

Company Snapshot

Headquartered in Basel, Switzerland, Lonza Group operates globally, serving over 100 markets. The company reported annual sales of CHF 6.7 billion in 2023, primarily driven by its Biologics and Small Molecules divisions, though its Capsules & Health Ingredients segment remains a significant contributor. Key brands within the nutraceutical space include Capsugel, renowned for its empty capsules, and specifically DRcaps, designed for delayed-release applications. With an employee base exceeding 18,000 worldwide, Lonza's scale and integrated capabilities position it as a formidable force across the supply chain, from ingredient manufacturing to finished product solutions.

Strategic Position and Recent Moves

Lonza's strategic focus over the past 12-24 months has reinforced its position as an integrated solutions provider, moving beyond simple component supply. In Q4 2024, Lonza announced a significant expansion of its capsule manufacturing capacity in Europe and North America, a direct response to increasing demand for advanced dosage forms. This expansion, valued at approximately CHF 150 million, underscores their commitment to maintaining market leadership in capsule technology against competitors such as ACG and CapsCanada. Furthermore, Lonza has been actively pursuing strategic partnerships. In early 2025, they formalised an agreement with a leading microbiome research firm to develop novel probiotic encapsulation technologies, aiming to enhance stability and targeted delivery. This move capitalises on the growing consumer interest in gut health and precision nutrition. Additionally, Lonza's Health Ingredients division has seen targeted product launches, such as a new line of science-backed ingredients for cognitive health introduced in Q1 2026, leveraging their expertise in formulation and clinical validation. Their investment in R&D for advanced delivery and functional ingredients demonstrates a clear strategy to capture higher value segments of the market.

What Manufacturers Can Learn

Lonza Group's trajectory offers several key insights for contract manufacturers and ingredient suppliers. Firstly, the emphasis on advanced delivery systems, exemplified by DRcaps, highlights a market demand for enhanced bioavailability and targeted release. Manufacturers who can integrate such technologies or offer bespoke solutions will gain a competitive edge. Secondly, Lonza's strategic partnerships in emerging areas like the microbiome signal the importance of staying abreast of scientific advancements and consumer trends. Ingredient suppliers should proactively develop clinically validated ingredients that align with these growing health categories. The market is moving towards efficacy and customisation, and Lonza's moves suggest that robust scientific backing and novel delivery are no longer premium features but becoming baseline expectations. Thirdly, their continuous investment in manufacturing capacity underscores the need for scalability and reliability in the supply chain. For smaller players, this means focusing on niche specialisations or agile production to differentiate themselves.

Risks and Headwinds

Despite its strong market position, Lonza faces several risks and headwinds. Regulatory scrutiny across global markets, particularly regarding novel ingredients and health claims, remains a constant challenge, requiring substantial investment in compliance and clinical validation. Competition within the empty capsule market, while Lonza holds a dominant share, is persistent from players like ACG and CapsCanada, who often compete on price or regional specialisation. The broader economic climate, including inflation and supply chain disruptions, continues to impact raw material costs and operational efficiency. Furthermore, any reputational damage from quality control issues or environmental concerns could significantly affect their B2B relationships. The sheer scale of Lonza's operations also presents an inherent challenge in maintaining agility and responding rapidly to highly fragmented market demands in the nutraceutical sector.

The B2B Verdict

For supplement businesses, Lonza Group is an indispensable entity to monitor. Their dominance in capsule technology makes them a critical supplier for many, and their strategic investments indicate the direction of advanced formulation and ingredient science. Businesses should not aim to compete directly with Lonza's scale but rather identify opportunities for partnership, particularly in novel ingredient development or specialised contract manufacturing where Lonza may seek external expertise. Staying informed about their product launches and technological advancements is crucial for understanding future market demands and maintaining a competitive edge in the evolving nutraceutical landscape.